0:00 Welcoming & Speaker Overview
2:08 Introduction (Dr. Kaspar Cottier)
5:11 Top Trends 'Creoptix Perspective' (Dr. Kaspar Cottier)
13:30 Conclusion (Dr. Kaspar Cottier)
15:09 Introduction (Dr. Thomas Schubert)
19:39 Top Trends '2bind Perspective' (Dr. Thomas Schubert)
27:49 Showcase 1: GCI to study Antibody / AG interactions (Dr. Thomas Schubert)
31:21 Showcase 2: GCI to study Drug / Target interactions (Dr. Thomas Schubert)
39:49 Conclusion (Dr. Thomas Schubert)
42:55 Q&A Session
In the following video Dr. Kaspar Cottier, CTO and Founder of Creoptix and Dr. Thomas Schubert, CEO at 2bind, will discuss the relevance of molecular interactions analysis in drug discovery and how new technologies are bridging the gap to tackle challenging systems in a virtual event. Watch the video to discover more about:
► Current trends and dynamics on molecular interaction analysis
► The importance of robust molecular binding characterization in antibody and small molecule development
► How to reliably screen and validate p38 targeting small molecule and biologics drug hits in only a few days
Learn more about the GCI and waveRAPID technologies and how they are being applied to accelerate discovery.
------------------------------------------------------
► More about 2bind: 2bind.com/
-------------------------------------------------------
► More about waveRAPID: www.creoptix.com/products/wav...
► About Creoptix: www.creoptix.com/about-us
► Get in touch with us: www.creoptix.com/contact
► Follow us on Linkedin: / creoptix
► Follow us on Twitter: / creoptix
-------------------------------------------------------
Creoptix AG
Zugerstrasse 76
8820 Waedenswil
Switzerland
Creoptix Inc.
c/o CliftonLarsonAllen LLP
111 South Bedford Street, Ste. 108
MA-01803 Burlington
USA